| The company's profit before tax in the quarter under review was Rs 27.96 crore, up 315.45 per cent over the profit of Rs 6.73 crore of the comparable quarter in the previous financial year. |
| Its net sales during the quarter jumped 32.44 per cent to Rs 104.75 crore from Rs 79.09 crore of the previous corresponding quarter. |
| For the financial year ended March 31, 2006, the company posted 66.15 per cent growth in net profits at Rs 108 crore, compared with the net profit of Rs 65 crore recorded in the previous financial year. Its profit before tax for the year stood at Rs 149 crore against Rs 104 crore last year, posting a growth of 43.26 per cent. |
| The company's total sales during the year under review stood at Rs 526 crore, representing a rise of 11.5 per cent over the sales of Rs 471 crore clocked in the financial year ended March 2005. |
| For the period, its sales of pharmaceuticals rose 26 per cent to Rs 364 crore over the last-year figure, primarily owing to sustained marketing and sales initiatives. |
| However, the company's generics business declined 13.1 per cent to Rs 55 crore during the year over the previous year because of a downturn in the retail trade business. During the period under review, the OTC business achieved a growth of 38.4 per cent on sales of Rs 72 crore. |
| This was due to consolidation of brands, launch of new products and line extensions during the year. Sales of the animal health segment at Rs 34 crore grew 19 per cent over the previous year. |
| This growth was spearheaded by cattle products and a series of rural penetration programmes, said a company release. |
| Novartis recommended a dividend of 200 per cent (Rs 10 per equity share of Rs 5 each) for the financial year ended March 2006. |
| The company also recommended an additional one-time dividend of 100 per cent (Rs 5 per equity share of Rs 5 each), this being the 10th anniversary of the Novartis India foundation. |
Top Section
Explore Business Standard